Durability of the first biologic in patients with Crohn's disease: A nationwide study from the epi-IIRN.

Ohad AtiaChagit FrissGili FochtRamit Magen RimonNatan LeddermanShira GreenfeldAmir Ben-TovYiska Loewenberg WeisbandEran MatzYuri GorelikYehuda ChowersIris DotanDan Turner

Published in: Journal of Crohn's & colitis (2023)

Durability of the first biologic in CD was highest for adalimumab-monotherapy. Combotherapy further increased the durability of adalimumab and infliximab. Unless otherwise indicated, our data may support using anti-TNFs as first-line biologics in CD, particularly adalimumab if monotherapy is advised.

Keyphrases

rheumatoid arthritis
ulcerative colitis
juvenile idiopathic arthritis
disease activity
combination therapy
open label
hidradenitis suppurativa
nk cells
electronic health record
big data
systemic lupus erythematosus
randomized controlled trial
machine learning
artificial intelligence
deep learning